Significant improvements in heart wall thickness, heart function and quality of life, as well as an excellent safety profile, were reported in an interim analysis of the BioVAT-HF clinical trial.
Exstent has appointed Matt Thompson its chief executive officer to lead the company’s next stage of global growth and expand access to its personalized external aortic support technology.
Tolpegin brings more than two decades of leadership experience with nonprofit medical organizations, including her role as the CEO of the Society of Cardiovascular Computed Tomography.
Naples Comprehensive Health (NCH) announced that Joseph Lamelas, MD, an internationally renowned cardiothoracic surgeon and pioneer in minimally invasive cardiac surgery, will join the NCH Rooney Heart Institute in Naples on Oct. 15.
Integration Health announces the acquisition of ECMO Advantage, combining the industry's two leading ECMO service providers to create the definitive national platform for ECMO program development, specialized staffing, transport and education services.
Biome Analytics is set to launch the Biome Virtual Analyst — a groundbreaking AI-powered tool that gives hospitals immediate answers to complex performance, clinical, and financial questions without sifting through dashboards or reports.
Biome Analytics has launched Biome IMPACT, a new AI-enabled methodology to support cardiovascular performance improvement. The framework helps health systems identify opportunities, align stakeholders and track measurable results—without adding to the team’s workload.
Biome Analytics is proud to welcome Javier Valle, MD—renowned interventional cardiologist and national quality leader—as our new chief medical officer. His deep clinical expertise and commitment to high-value care will help shape the future of cardiovascular performance improvement.
Hospitals can now measure and improve outcomes through the lens of social and economic disparities by integrating social determinants of health (SDOH) directly into their performance analytics.
Special T MRI, an independent, state-of-the-art imaging center located in Fenton, Missouri, is proud to announce the launch of its advanced cardiac MRI imaging program aimed at enhancing early detection and management of heart disease through non-invasive cardiac MRI technology.
NASA is constantly working toward enhancing astronaut safety through the development of next-generation spacesuits. In collaboration with the German medical technology developer Corscience, a crucial milestone has been achieved in advancing the design and functionality of spacesuits for the upcoming Artemis lunar missions.
This achievement highlights Positron's commitment to providing innovative imaging solutions that enable healthcare providers to elevate patient care and achieve superior clinical outcomes.
This partnership underscores Peak Heart & Vascular’s dedication to improving patient outcomes through research, education and the latest medical technologies, ensuring they remain at the forefront of cardiovascular care in Arizona.
Following its recent $43 million Series B funding, the company is expanding its data integration capabilities to include a broader range of devices, including wearables, heart failure monitoring, and remote patient monitoring.
Congratulations to Stanford Medicine on winning the 2023 Hearst Health Prize for its artificial intelligence solution that helps identify patients at risk for heart attack by scoring incidental coronary artery calcium (CAC) on non-gated chest CTs.
Late-Breaking Science sessions reveal revolutionary findings on severe aortic stenosis and mild-to-severe mitral regurgitation identification through innovative AI technology.
Researchers and engineers at Mayo Clinic and Ultromics developed technology that can detect HFpEF using a single A4C echocardiogram clip, to help clinicians detect a complex form of heart failure easily and accurately.
The Midwest company will begin offering EchoSolv, an artificial intelligence clinical decision support platform designed to help detect severe aortic stenosis, to providers throughout the country.
PulseAI, a leader in the development of cutting-edge AI-powered ECG software, has released the results of a clinical study that has shown the superiority of its deep learning AI over the Apple Watch ECG algorithm in the detection of atrial fibrillation.
NAPLES, Fla. – February 20, 2023 The NCH Healthcare System is proud to announce a $20 million naming gift from the Rooney Foundation, which is the philanthropic arm of the former U.S. Representative for Florida's 19th congressional district and his wife, Francis and Kathleen Rooney. In recognition of increasing their $8 million pledge announced last July, the entire cardiac program across NCH Healthcare System will be renamed “The Rooney Heart Institute.”
NAPLES, Fla. – February 21, 2023 On the heels of our historic $20 Million gift announcement made last week, NCH is proud to announce yet a second $20 million naming gift in as many weeks from Diana and Don Wingard. This generous gift will provide the necessary funds to ensure that the NCH Stroke program continues to provide the highest level of care and treatment to patients in Southwest Florida. Additionally, in recognition of the extraordinary pledge, the entire stroke program across NCH will be renamed the “Wingard Stroke Institute.”
When using this service, patients have the ability to upload and share data without limitations. From radiology CDs to PDFs or JPG files, patients can use their smartphone connected to the Patient Image Exchange app and upload images, share lab results, immunizations records, nurses’ notes, dental images and much more.
Ancora Heart has hired senior financial leader David J. Tucker as its chief financial officer. This is the company's second C-suite hire in 2022, following the addition of Mark Miles as chief commercial officer in June.
Geneticure, a global leader in the genetic variability of response to hypertension treatments, presented data at the 2022 American Heart Association Scientific Sessions meeting from a recent clinical study in which they were able to successfully predict patients who will respond to renal denervation (RDN). In addition, the Geneticure test for renal denervation also identified patients with an increase in blood pressure, following the procedure.
Long-awaited milestone gives physicians and their patients greater access to prescription cardiac arrhythmia detection solutions, including the company’s Cardea SOLO™ ECG System
Merge Healthcare Incorporated (NASDAQ:MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, entered into an agreement to provide its Merge Hemo(TM) solution to Baptist Health System of Birmingham, Alabama.
Medtronic plc (NYSE: MDT) was recognized as one of the world's leading companies for sustainability with its ranking on the Dow Jones Sustainability North America Index (DJSI North America) for the eighth consecutive year.
Addenbrooke’s Hospital’s Emergency Department (ED), part of Cambridge University Hospitals NHS Foundation Trust, has become the first UK site to install two Stratus® CS 200 Acute Care Diagnostic cardiac analysers. The technology from Siemens Healthcare Diagnostics is enabling rapid diagnosis of cardiovascular disease (CVD) to quickly determine an appropriate treatment plan.
Abbott announced today that it has completed its acquisition of Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies.
BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, today announced CE approval and the results of a pilot study into the performance of BioMonitor 2.
Stereotaxis, Inc. (NASDAQ:STXS) and Westmead Hospital in Australia today announced findings of a recent study comparing the stability of a Niobe(R) remote magnetic navigation system catheter group and a manually controlled catheter group in a validated cardiac wall motion simulator.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has closed its acquisition of CardiAQ Valve Technologies, Inc., a privately held company and developer of a transcatheter mitral valve replacement system.
In the 40 years between 1970-2010, the proportion of patients with diabetes undergoing coronary artery bypass grafting (CABG) escalated from 7% to 37%. The results of a large study from Cleveland Clinic just published in The Journal of Thoracic and Cardiovascular Surgery, the official publication of the American Association for Thoracic Surgery (AATS), documents the five-fold increase in the proportion of patients with diabetes undergoing this procedure between 1970 and 2010.
Colibri Heart Valve LLC, a privately held emerging medical device company, has received an Issue Notification from the U.S. Patent and Trademark Office regarding the forthcoming granting of its "Percutaneous Replacement Heart Valve and a Delivery and Implantation System."
The American College of Cardiology is collaborating with Apollo Hospitals in India to provide the College’s guideline-driven educational content to physicians participating in Apollo’s Medvarsity e-learning program, India’s first medical e-learning venture.
Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, announced it will file a submission today with the U.S. Food and Drug Administration (FDA) for 510(k) clearance to market its Pantheris image-guided atherectomy device for the treatment of patients with peripheral arterial disease (PAD).
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced today that it has entered into a corporate partnership with Fenway Park and will be bringing its Impella Mobile Learning Lab to the historic baseball stadium tomorrow.
The Society of Cardiovascular Computed Tomography (SCCT) announces the recipients of the 2015 Arthur S. Agatston Cardiovascular Disease Prevention Awards, which were recently presented at the 10th Annual Scientific Meeting (SCCT2015), held in Las Vegas, Nevada.
Medtronic plc (NYSE: MDT) today announced the launch of its Entrust(TM) delivery system in the United States. The new Entrust delivery system enables physicians to place Medtronic's EverFlex(TM) self-expanding peripheral stent, while maintaining a low profile and providing the ease of a one-handed device.
TriVascular Technologies, Inc. (NASDAQ:TRIV) announced today that the U.S. Food and Drug Administration (FDA) approved the Ovation iX Abdominal Stent Graft System. Delivery system enhancements of Ovation iX, which stands for integrated exchange, are designed to provide physicians with additional flexibility for even more predictable deployment and greater ease of use.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today reported net income for the quarter ended June 30, 2015 of $112.7 million, or $1.02 per diluted share.
Siemens Healthcare Diagnostics has launched the hand-held and portable Xprecia Stride Coagulation Analyser to deliver fast, reliable testing in any clinical environment.
Vital Images, Inc. (Vital) will debut its 510(k) FDA-cleared CT Myocardial Perfusion application at the 10 th Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT) in Las Vegas, July 16-19.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has agreed to acquire CardiAQ Valve Technologies, Inc., a privately held company and developer of a transcatheter mitral valve replacement system.
Cardiovascular Systems, Inc. (NASDAQ:CSII) (CSI), today announced that it has received FDA clearance for its new ViperWire Advance® Peripheral Guide Wire with Flex Tip for their Peripheral Orbital Atherectomy Systems (OAS). The new guide wire provides physicians with improved flexibility, navigation and ease-of-use—particularly in hard-to-reach, tortuous vessels—when treating arterial calcium associated with peripheral artery disease (PAD).
